Protective Effect of HMG-CoA Reductase Inhibitor Rosuvastatin on Doxorubicin-Induced Cognitive Impairment, Oxidative Stress and Neuroinflammation: Possible Role of CREB, ERK1/2, and BDNF

ArticleAçık Erişim

Özet

During or after chemotherapy, cognitive impairments characterized by forgetfulness, difficulty concentrating, and depressive and anxiety-like symptoms are observed. There is limited research examining the effects of rosuvastatin (RVS), an HMG-CoA reductase inhibitor, in the context of neuroinflammation-related cognitive disruption. Here, we aimed to investigate the neuroprotective potential of RVS against doxorubicin (DOX)-induced cognitive impairments. Experimental groups were planned as control (normal saline, intraperitoneal), DOX (total cumulative dose 10 mg/kg, intraperitoneal), RVS (10 mg/kg, oral, 20 days), and RVS + DOX. Efficacy was monitored by applying a battery of behavioral assessments, as well as biochemical, genetic, histopathological, and immunohistochemical examinations. Results from Morris water maze (MWM), passive avoidance, locomotion activity, and elevated plus maze (EPM) tests showed that DOX administration caused behavioral disorders. Moreover, DOX increased the levels of inducible nitric oxide synthase (iNOS), malondialdehyde (MDA), and tumor necrosis factor-α (TNF-α), while decreasing the levels of interleukin-10 (IL-10), glutathione (GSH), superoxide dismutase, catalase (SOD), endothelial nitric oxide (eNOS), and catalase (CAT). Co-treatment with RSV significantly attenuated DOX-induced behavioral changes and oxidative stress markers. In addition, similar to the immunohistochemical results, we determined that it increased the expression levels of extracellular signal-related kinases 1/2 (ERK1/2), cyclic adenosine monophosphate response element binding protein (CREB), and brain-derived neurotrophic factor (BDNF) and restored the histopathological structure of the brain. Therefore, these results indicated that RSV has a neuroprotective effect against DOX-induced cognitive impairment by reducing neurobehavioral impairments, exerting antioxidant and anti-inflammatory effects, and modulating brain growth factors. © The Author(s) 2025.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/10873Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1007/s11481-025-10213-6Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorYeni, Yesim
dc.contributor.authorCicek, Betul
dc.contributor.authorHacimuftuoglu, Ahmet
dc.contributor.authorOzkaraca, Mustafa
dc.contributor.authorLacin, Burak Batuhan
dc.date.accessioned2026-10-18T20:25:59.605411553Z
dc.date.available2026-10-18T20:25:59.605411553Z
dc.date.issued2025
dc.description.abstractDuring or after chemotherapy, cognitive impairments characterized by forgetfulness, difficulty concentrating, and depressive and anxiety-like symptoms are observed. There is limited research examining the effects of rosuvastatin (RVS), an HMG-CoA reductase inhibitor, in the context of neuroinflammation-related cognitive disruption. Here, we aimed to investigate the neuroprotective potential of RVS against doxorubicin (DOX)-induced cognitive impairments. Experimental groups were planned as control (normal saline, intraperitoneal), DOX (total cumulative dose 10 mg/kg, intraperitoneal), RVS (10 mg/kg, oral, 20 days), and RVS + DOX. Efficacy was monitored by applying a battery of behavioral assessments, as well as biochemical, genetic, histopathological, and immunohistochemical examinations. Results from Morris water maze (MWM), passive avoidance, locomotion activity, and elevated plus maze (EPM) tests showed that DOX administration caused behavioral disorders. Moreover, DOX increased the levels of inducible nitric oxide synthase (iNOS), malondialdehyde (MDA), and tumor necrosis factor-α (TNF-α), while decreasing the levels of interleukin-10 (IL-10), glutathione (GSH), superoxide dismutase, catalase (SOD), endothelial nitric oxide (eNOS), and catalase (CAT). Co-treatment with RSV significantly attenuated DOX-induced behavioral changes and oxidative stress markers. In addition, similar to the immunohistochemical results, we determined that it increased the expression levels of extracellular signal-related kinases 1/2 (ERK1/2), cyclic adenosine monophosphate response element binding protein (CREB), and brain-derived neurotrophic factor (BDNF) and restored the histopathological structure of the brain. Therefore, these results indicated that RSV has a neuroprotective effect against DOX-induced cognitive impairment by reducing neurobehavioral impairments, exerting antioxidant and anti-inflammatory effects, and modulating brain growth factors. © The Author(s) 2025.
dc.description.sponsorshipOpen access funding provided by the Scientific and Technological Research Council of T\u00FCrkiye (T\u00DCB\u0130TAK).
dc.identifier.doi10.1007/s11481-025-10213-6
dc.identifier.eissn1557-1904
dc.identifier.issn1557-1890
dc.identifier.issue1
dc.identifier.pmcidPMC12075306
dc.identifier.pmid40358798
dc.identifier.scopus2-s2.0-105004909377
dc.identifier.startpage53
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/10873
dc.identifier.volume20
dc.identifier.wosWOS:001487356200001
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofJournal of Neuroimmune Pharmacology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCognitive impairment
dc.subjectDoxorubicin
dc.subjectNeuroinflammation
dc.subjectNeuroplasticity
dc.subjectRosuvastatin
dc.subjectAnimals
dc.subjectAntibiotics, Antineoplastic
dc.subjectBrain-Derived Neurotrophic Factor
dc.subjectCognitive Dysfunction
dc.subjectCyclic AMP Response Element-Binding Protein
dc.subjectHydroxymethylglutaryl-CoA Reductase Inhibitors
dc.subjectMale
dc.subjectMAP Kinase Signaling System
dc.subjectNeuroinflammatory Diseases
dc.subjectNeuroprotective Agents
dc.subjectOxidative Stress
dc.subjectRats
dc.subjectRats, Wistar
dc.subjectRosuvastatin Calcium
dc.subjectamyloid beta protein
dc.subjectantioxidant
dc.subjectbrain derived neurotrophic factor
dc.subjectcatalase
dc.subjectcyclic AMP responsive element binding protein
dc.subjectinterleukin 10
dc.subjectketamine
dc.subjectmalonaldehyde
dc.subjectmitogen activated protein kinase
dc.subjectnitric oxide
dc.subjectsuperoxide dismutase
dc.titleProtective Effect of HMG-CoA Reductase Inhibitor Rosuvastatin on Doxorubicin-Induced Cognitive Impairment, Oxidative Stress and Neuroinflammation: Possible Role of CREB, ERK1/2, and BDNF
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus11
rdl.citation.wos10
rdl.departmentFaculty of Medicine, Department of Physiology, Erzincan Binali Yildirim University, Erzincan, Turkey.
rdl.oa.statusgold
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)